Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001609351-19-000072
Filing Date
2019-11-07
Accepted
2019-11-07 16:35:33
Documents
70
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q spark-201993010xq.htm   iXBRL 10-Q 1864652
2 EXHIBIT 31.1 spark-2019930exx311.htm EX-31.1 21900
3 EXHIBIT 31.2 spark-2019930exx312.htm EX-31.2 21899
4 EXHIBIT 32.1 spark-2019930exx321.htm EX-32.1 6990
5 EXHIBIT 32.2 spark2019930ex-322.htm EX-32.2 6874
  Complete submission text file 0001609351-19-000072.txt   6598100

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT once-20190930.xsd EX-101.SCH 40923
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT once-20190930_cal.xml EX-101.CAL 80124
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT once-20190930_def.xml EX-101.DEF 217822
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT once-20190930_lab.xml EX-101.LAB 631885
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT once-20190930_pre.xml EX-101.PRE 367272
24 EXTRACTED XBRL INSTANCE DOCUMENT spark-201993010xq_htm.xml XML 815256
Mailing Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Business Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 888-772-7560
Spark Therapeutics, Inc. (Filer) CIK: 0001609351 (see all company filings)

EIN.: 462654405 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36819 | Film No.: 191200897
SIC: 2836 Biological Products, (No Diagnostic Substances)